Publications by authors named "U De Giorgi"
Introduction: Prostate cancer (PCa) is the second most common cancer diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment strategies have evolved, including the use of androgen receptor pathway inhibitors (ARPIs) and poly (ADP-ribose) polymerase inhibitors (PARPis).
Areas Covered: This review evaluates the clinical efficacy, safety, and future potential of combining talazoparib, a potent PARPi, with enzalutamide, a strong androgen receptor (AR) antagonist.
Testicular germ cell tumors (TGCTs), the most common malignancies affecting young men, are characterized by high sensitivity to cisplatin-based chemotherapy, which leads to high cure rates even in metastatic disease. However, approximately 30% of patients with metastatic TGCTs relapse after first-line treatment and those who can be defined as platinum-refractory patients face a very dismal prognosis with only limited chemotherapy-based treatment options and an overall survival of few months. Hence, to understand the mechanisms underlying cisplatin resistance is crucial for developing new treatment strategies.
View Article and Find Full Text PDFArticle Synopsis
- About 20% of prostate cancer patients have alterations in HRR genes like BRCA1/2, which are important biomarkers for treatment with PARP inhibitors like Olaparib, currently approved for metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations in Italy.
- A survey of 108 oncologists revealed that only 52.8% regularly test all metastatic prostate cancer patients for BRCA mutations, and many face challenges such as long wait times and unclear procedures.
- These obstacles hinder the effective implementation of genetic testing, limiting access to personalized PARP inhibitor treatment and highlighting the need for improved molecular testing processes in clinical settings.
Article Synopsis
- The IMDC score is crucial for predicting outcomes and guiding treatment in patients with metastatic renal cell carcinoma (mRCC), especially when starting therapy with nivolumab.
- A multicenter study analyzed 492 mRCC patients to see how changes in IMDC categories affected their overall survival (OS) and progression-free survival (PFS) after starting nivolumab.
- Results indicated that patients maintaining or improving their IMDC category had better survival outcomes compared to those whose condition worsened, highlighting the importance of IMDC monitoring in mRCC treatment.